Company intelligence / Profile preview

Y Collection

Daejeon, Daejeon Metropolitan City, South Koreaen.ycollection.kr ↗

Ownership: Private
Development stage: Other

Overview

Y-Biologics is a leading Korean biotech specializing in the discovery and development of novel antibody therapeutics for immuno-oncology. The company has developed proprietary platforms for generating human antibodies and bispecific T-cell engagers, with a pipeline focused on next-generation immunotherapies targeting the tumor microenvironment. It has entered into global licensing agreements with major pharma partners but does not yet have marketed products.[4][5]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate (potential, based on platform capabilities)
Industry: Biotech

Partnerships

Pierre Fabre (worldwide exclusive license agreement for a family of human antibodies generated by the Ymax®‑ABL library)[5]

Beyond the preview

Go deeper on Y Collection.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y Collection.

Explore the full profile